EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors

Lipids - 2003
Laura J. Stevens1, Wen Zhang1, Louise Peck2, Thomas Kuczek3, Nels Grevstad3, Anne Mahon1, Sydney S. Zentall4, L. Eugene Arnold5, John Burgess1
1Department of Foods and Nutrition, Purdue University, 700 West State St., G1, West, Lafayette, IN, 47907
2Department of Food Science & Human Nutrition, Washington State University, Pullman, Washington, 99164
3Department of Statistics, Purdue University, West Lafayette, Indiana, 47907
4Department of Educational Studies, Purdue University, West Lafayette, Indiana, 47907
5Department of Psychiatry, Ohio State University, Columbus, Ohio, 43210

Tóm tắt

AbstractThis pilot study evaluated the effects of supplementation with PUFA on blood FA composition and behavior in children with Attention‐Deficit/Hyperactivity Disorder (AD/HD)‐like symptoms also reporting thirst and skin problems. Fifty children were randomized to treatment groups receiving either a PUFA supplement providing a daily dose of 480 mg DHA, 80 mg EPA, 40 mg arachidonic acid (AA), 96 mg GLA, and 24 mg α‐tocopheryl acetate, or an olive oil placebo for 4 mon of doubleblind parallel treatment. Supplementation with the PUFA led to a substantial increase in the proportions of EPA, DHA, and α‐tocopherol in the plasma phospholipids and red blood cell (RBC) total lipids, but an increase was noted in the plasma phospholipid proportions of 18∶3n‐3 with olive oil as well. Significant improvements in multiple but outcomes (as rated by parents) were noted in both groups, but a clear benefit from PUFA supplementation for all behaviors characteristic of AD/HD was not observed. For most outcomes, improvement of the PUFA group was consistently nominally better than that of the olive oil group; but the treatment difference was significantly, by secondary intent‐to‐treat analysis on only 2 out of 16 outcome measures: conduct problems rated by parents (−42.7 vs. −9.9%, n=47, P=0.05), and attention symptoms rated by teachers (−14.8 vs. +3.4%, n=47, P=0.03). PUFA supplementation led to a greater number of participants showing improvement in oppositional defiant behavior from a clinical to a nonclinical range compared with olive oil supplementation (8 out of 12 vs. 3 out of 11, n=33, P=0.02). Also, significant correlations were observed when comparing the magnitude of change between increasing proportions of EPA in the RBC and decreasing disruptive behavior as assessed by the Abbreviated Symptom Questionnaire (ASQ) for parents (r=−0.38, n=31, P<0.05), and for EPA and DHA in the RBC and the teachers' Disruptive Behavior Disorders (DBD) Rating Scale for Attention (r=−0.49, n=24, P<0.05). Interestingly, significant correlations were observed between the magnitude of increase in α‐tocopherol concentrations in the RBC and a decrease in scores for all four subscales of the teacher's DBD (Hyperactivity, r=−0.45; Attention, r=−0.60; Conduct, r=−0.41; Oppositional/Defiant Disorder, r=−0.54; n=24, P<0.05) as well as the ASQ for teachers (r=−0.51, n=24, P<0.05). Thus, the results of this pilot study suggest the need for further research with both n−3 FA and vitamin E in children with behavioral disorders.

Từ khóa


Tài liệu tham khảo

American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders

Arnold L.E., 2000, Contemporary Diagnosis and Management of ADHD

10.1038/scientificamerican0998-66

10.1177/000992289703600702

10.1017/S0954579499002230

10.1016/S0006-3223(98)00240-6

10.1016/S1056-4993(18)30107-X

10.1177/108705479900300103

10.1111/j.1939-0025.1985.tb03433.x

10.1111/j.1939-0025.1966.tb02414.x

10.1001/jama.285.1.60

10.1016/S0021-9258(20)78929-5

10.1093/jn/66.4.565

10.1080/07315724.1986.10720126

10.1111/j.1398-9995.1992.tb00675.x

10.1016/S0140-6736(82)92784-2

10.1111/j.1365-2133.1984.tb04698.x

10.1016/0262-1746(82)90019-1

Bordoni A., 1988, Evening Primrose Oil (Efamol) in the Treatment of Children with Atopic Eczema, Drugs Exp. Clin. Res., 14, 291

10.1093/ajcn/71.1.352s

10.1093/ajcn/71.1.349s

10.1159/000045271

10.1016/S0002-8223(97)00753-0

10.1093/ajcn/64.2.210

Carsons S., 2001, A Review and Update of Sjogren's Syndrome: Manifestations, Diagnosis, and Treatment, Am. J. Manag. Care, 7, S433

10.1016/S0952-3278(98)90136-3

10.1159/000051779

10.1111/j.1440-0960.1990.tb00642.x

10.1046/j.1525-1470.1999.00022.x

10.1054/plef.2000.0194

10.1054/plef.2000.0195

10.1054/plef.2001.0281

10.1016/S0387-7604(98)00079-5

10.1093/schbul/22.3.455

10.1016/S0920-9964(01)00292-4

10.1016/S0924-9338(00)00399-0

Holman R.T., 1995, Patients with Anorexia Nervosa Demonstrate Deficiencies of Selected Essential Fatty Acids, Compensatory Changes in Nonessential Fatty Acids and Decreased Fluidity of Plasma Lipids, J. Nutr., 125, 901

10.1159/000049385

Rudin D., 1981, The Major Psychoses and Neuroses as ω‐3 Essential Fatty Acid Deficiency Syndrome: Substrate Pellagra, Biol. Psychiatry., 16, 837

10.1093/ajcn/62.4.761

10.1016/0031-9384(95)02207-4

10.1093/ajcn/71.1.327S

10.1002/(SICI)1097-4547(19990615)56:6<565::AID-JNR2>3.0.CO;2-H

Reisbick S., 1985, n‐3 Fatty Acids in the Brain and Retina: Evidence for Their Essentiality, Nutr. Rev., 44, 285

10.1007/BF02543972

10.1016/0031-9384(94)90128-7

Connor W.E., 1988, The Effects of n‐3 Fatty Acid Deficiency and Repletion upon the Fatty Acid Composition and Function of the Brain and Retina, Prog. Clin. Biol. Res., 282, 275

10.1093/ajcn/62.1.1

10.1007/BF02637069

10.1016/S0165-0327(97)00166-3

10.1001/archpsyc.56.5.407

10.1002/(SICI)1099-1077(199601)11:1<39::AID-HUP742>3.0.CO;2-#

10.1176/appi.ajp.158.12.2071

10.1007/BF00916467

10.1016/S0278-5846(01)00254-8

10.1067/mpd.2001.116050

10.1139/y59-099

10.1007/BF02535281

10.1079/BJN19890096

10.1007/BF02546012

Kuo C.F., 1995, Deficiency of Vitamin E and Selenium Enhances Calcium‐Independent Phospholipase A2 Activity in Rat Lung and Liver, J. Nutr., 125, 1419

Conners C., 1990, Conners' Abbreviated Symptom Questionnaire

10.1016/S0002-7138(10)60120-3

10.1177/108705479600100105

10.1097/00004583-199203000-00006

Conners C.K., 1995, Conners' Continuous Performance Test Computer Program: User's Manual

Woodcock R., 1989, Woodcock‐Johnson Psycho‐Educational Battery‐Revised (WJ‐R)

10.1037/1040-3590.3.4.603

10.1001/archpsyc.1967.01730280094011

10.1097/00004583-199704000-00016

10.1177/073428299000800303

Wainwright P., 1993, Lipids, Learning and the Brain: Fats in Infant Formulas

10.1016/S0022-3476(06)80735-3

10.1177/009286159102500311

10.1016/S0022-3956(98)00058-2

Conners C.K., 1990, Conners' Rating Scale Manual

10.1002/actp.1984.010350121

Holman R., 1981, New Trends in Nutrition, Lipid Research, and Cardiovascular Diseases, 25

10.1007/s004310050184

10.1016/0262-1746(83)90006-9

10.1016/0925-4439(92)90063-S

10.1007/s11745-001-0805-6

10.1111/j.1471-4159.1963.tb09855.x

10.1007/s11745-000-0497-y

10.1016/S0361-9230(01)00551-2

10.1007/s11745-998-0224-8

10.1007/BF02523832

10.1093/jn/126.suppl_4.1086S

10.1093/ajcn/52.1.120

10.1093/jn/128.9.1537

10.1016/S0022-2275(20)32071-X

10.1016/S0022-2275(20)38463-7

10.1002/dev.420270705

10.1037/0012-1649.33.3.387

10.1192/bjp.181.1.22

10.3177/jnsv.45.655

10.1172/JCI118507

10.1016/S0920-9964(02)00284-0

Wolraich M.L., 1990, Stimulant Medication Use by Primary Care Physicians in the Treatment of Attention Deficit Hyperactivity Disorder, Pediatrics, 86, 95, 10.1542/peds.86.1.95

10.1016/S0022-3956(01)00048-6

Thông tin
Thông tin xuất bản

Lipids

Thông tin tác giả